1986 - 1996

• A medical need is identified and the development of a new biomaterial commences. During subsequent years material, product and production development takes place and the technology is verified through preclinical trials.

1997

• The Company acquires a Swedish patent for Artelon® hydrolyzable fiber polymers for use in temporary implants.
• New share issue raises MSEK 67,5 less costs and the Company is floated on the Stockholm Stock Exchange.
• The first cruciate ligament (ACL) operations on human patients using implants from Artimplant are carried out within the framework of a pilot study.

1998

• The Company acquires Gothenburg Medical Center, a clinic specializing in sports-related injuries.

1999

• Pilot studies in the treatment of damaged thumb ligament and thumb base osteoarthritis are initiated.
• Artimplant’s first multicenter trial in ACL reconstruction begins.
• Artimplant begins cooperation with Mölnlycke Health Care AB in the field of wound care.

2000

• Operations in the first multicenter trial in ACL reconstruction are concluded. The second multicenter ACL reconstruction trial begin.
• Artimplant’s Artelon® patent is approved in the USA and Europe.
• The marketing organization is expanded

2001

• Artimplant’s quality assurance system is certified by Lloyds Register Quality Assurance.
• Artimplant’s first product, the Artelon® ACL Augmentation Device, is granted CE-certification, and can now be marketed in Europe.
• The task of building up the Company’s own marketing and sales organization ceased during the autumn.
• Products and material technology will be commercialized through the granting of licenses to leading companies with a global presence.

2002

• Agreement on wound care signed with Mölnlycke Health Care AB.
• An extensive restructuring program is commenced to reduce the Company’s cost base.

2003

• The Company signs an agreement with Atlantech for sales in the UK of its Artelon® ACL Augmentation Device.
• Artimplant’s Artelon® CMC Spacer for treating thumb base osteoarthritis receives clearance for marketing in Europe.
• Artelon® Surgical Suture is given the clearance for sales on the American market.
• The subsidiary Gothenburg Medical Center is sold.

2004

• Artelon® CMC Spacer receives clearance for marketing on the US market.
• Licensing agreement signed with Small Bone Innovations.
• A licensing agreement is signed with Biomet Inc. for the production of SportMesh™.
• Cooperation with Atlantech for the sale of Artelon® Augmentation Device ACL is concluded.
• Cooperation between Artimplant and Mölnlycke Health Care within wound care is concluded.

2005

• Four new licensing and development agreements are signed with Small Bone Innovations.
• A distribution agreement for Artelon® Surgical Suture in North America is signed with ArthroCare.
• Artelon® implant for reinforcing rotator cuffs is cleared for marketing in Europe.
• Office opened in the United States.

2006

• The Company receives clearance for marketing of the SportMesh™ rotator cuff implant in the USA.
• Four new Spacer products for the treatment of osteoarthritis in the hand and foot are granted clearance for marketing in Europe.
• The product Artelon® Augmentation Device ACL is discontinued.
• The sale of Artelon® CMC Spacer to end-customers increases by over 600% compared with 2005.

2007

• The Company´s sales increase markedly and cashflow improves considerably.
• The FDA grants clearance to market Artelon® Tissue Reinforcement for soft tissue reinforcement in several new indications in the USA.
• Two new Spacer products for osteoarthritis in the hand are granted clearance by the FDA for marketing in the USA.

2008

• Sales of Artelon® Tissue Reinforcement increase significantly whilst there is a lack of growth in sales of Artelon® Spacer.
• Artimplant is initiating new development projects for the treatment of knee joint osteoarthritis and osteoarthritis in the facet joint in the spine.
• Agreement signed with BioMedtrix regarding distribution in the USA of Artelon® CCL for cruciate ligament reconstruction in dogs.
  

2009

• Sales double and product sales to end-customers and distributors multiply, increasing its share of total sales to 37% (15).
• The agreement with Small Bone Innovations is renegotiated, making it non-exclusive from 2009.
• All patients are enrolled for the American post-market study of Artelon® Tissue Reinforcement for the treatment of patients
  with tears in the rotator cuff tendons.
• The first patients are included in a clinical study for the treatment ofosteoarthritis in the facet joint in the spine with an Artelon implant .
• Product design and procedure are developed further for Artelon® CCL.
• The first dogs in a prospectiveinvestigation in the USA undergo cruciate ligamentreconstruction using Artelon® CCL.